Drug trial results and the stock moves that follow

26 resultsPublic companies only
Met endpoint

ARIKAYCE

Phase 3 n=425 Mycobacterium Infections, Nontuberculous

Insmed INSM

24h stock move +8.25%
Page 2 of 2

Daily roundups

For information only. Not investment or medical advice. Prices are historical, from consolidated market data, and may contain errors. Always check the original source.